Peripheral nervous system (PNS) disease is a component of systemic lupus erythematosus (SLE) disease activity and has a significant negative impact on health-related quality of life.
Researchers evaluated the frequency of polyautoimmunity and its associated factors in a large retrospective cohort of patients with systemic lupus erythematosus.
GlaxoSmithKline announced positive results from the phase 3 BLISS-LN trial of belimumab for the treatment of active lupus nephritis in adult patients.
For patients with systemic lupus erythematosus (SLE), anifrolumab is associated with improved response at 52 weeks versus placebo.
The FDA has granted Fast Track designation for itolizumab (EQ001; Equillium) for the treatment of lupus nephritis.
Researchers assessed the effect of belimumab vs placebo on antiphospholipid antibodies from 2 large randomized controlled trials, BLISS-76 and BLISS-52.
Voclosporin was found to be superior to standard-of-care treatment in patients with lupus nephritis, according to data from the phase 3 AURORA trial.
Researchers investigated and compared the rates, risks, and risk factors for atrial fibrillation among Medicaid recipients with systemic lupus erythematosus (SLE) and age- and sex-matched Medicaid recipients without SLE.
Although the first phase 3 trial of anifrolumab did not meet its primary end point, other study end points that were met suggested a clinical benefit for the monoclonal antibody in systemic lupus erythematosus.
Researchers addressed the association between cardiovascular risk and glucocorticoids in patients with systemic lupus erythematosus.
